Levsinex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levsinex

What is Levsinex?

Levsinex is a brand-name medication containing hyoscyamine sulfate, an anticholinergic and antispasmodic agent. It belongs to a class of drugs derived from belladonna alkaloids and is designed to influence the activity of certain muscles and glands within the body.

Mechanism of Action

The active ingredient in Levsinex works by blocking the action of acetylcholine, a neurotransmitter that sends signals to various muscles and organs. By inhibiting these signals, the medication helps to relax smooth muscle tissue and reduce the secretions of certain glands.

Levsinex is specifically formulated as a timed-release capsule. This delivery system allows the medication to be released gradually into the bloodstream, extending the duration of its effects compared to immediate-release versions of hyoscyamine.

Primary Uses

Levsinex is utilized in the management of various gastrointestinal and visceral conditions characterized by spasms or hypermotility. Its primary applications include:

  • Gastrointestinal Disorders: It is used as adjunctive therapy to treat peptic ulcers, irritable bowel syndrome (IBS), neurogenic bowel disturbances, and functional gastrointestinal disorders.
  • Antispasmodic Effects: The medication helps control hypermotility in the lower urinary tract and can be used to treat symptoms associated with infant colic or biliary colic.
  • Secretory Control: It may be used to reduce excessive secretions, such as those occurring in rhinitis or during anesthesia to decrease salivation and respiratory tract secretions.
  • Other Applications: It is sometimes employed in the treatment of partial heart block associated with vagal activity and as an associative treatment for certain symptoms of Parkinsonism, such as tremors and rigidity.

Regulatory References

  1. FDA DailyMed
  2. FDA Labeling for Hyoscyamine Sulfate

What side effects are possible with Levsinex?

Possible Side Effects and Safety Information

The adverse reactions associated with Levsinex (hyoscyamine sulfate) are primarily manifestations of its anticholinergic (or muscarinic-cholinergic receptor blocking) activity. The severity and frequency of these effects are generally dose related, and they are typically reversible upon discontinuation of the drug.

Adverse Reactions

Commonly reported side effects reflect the drying action of the medication and include dry mouth (xerostomia), constipation, blurred vision, dizziness, drowsiness, urinary hesitancy and retention, headache, and light sensitivity (photophobia). Effects may occur across several system-organ classes, including the nervous, ocular, cardiovascular (e.g., tachycardia, palpitations), and gastrointestinal systems.

Serious Safety Information

Clinically significant adverse reactions documented in regulatory sources include psychosis (characterized by confusion, disorientation, hallucinations, or memory loss), which generally resolves upon discontinuation. Due to decreased sweating (anhidrosis), heat prostration (fever and heat stroke) can occur in the presence of high environmental temperatures. Diarrhea may be an early symptom of incomplete intestinal obstruction in certain patients and requires immediate discontinuation if suspected. Severe allergic reactions and anaphylaxis have been reported.

Safety Restrictions and Populations at Risk

The use of Levsinex is contraindicated in patients with conditions such as glaucoma, obstructive uropathy, obstructive diseases of the gastrointestinal tract (like paralytic ileus), and myasthenia gravis. Caution is advised for patients with autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure, and hypertension. Geriatric patients are especially susceptible to anticholinergic side effects like confusion and urinary retention, and caution is warranted for all patients in activities requiring mental alertness, such as driving.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

An overdose of Levsinex (Hyoscyamine Sulfate) results from excessive anticholinergic effects, leading to specific, officially documented signs.

Documented Overdose Presentations Signs and Symptoms
CNS, Ophthalmic, and Systemic CNS stimulation, headache, blurred vision, dilated pupils, hot dry skin, tachycardia, and urinary difficulty.
Severe Outcomes Paralysis of the respiratory muscles, severe fever, and intense excitement.

In the event of a suspected overdose, immediate emergency medical attention must be sought, and the user should contact a Poison Control Center.

Mandated Interventional Management

The official regulatory profile details specific measures for confirmed overdose. Immediate lavage of the stomach is a documented procedure. The regulatory labeling specifies that physostigmine injection is a measure to be taken, administered intravenously up to a total dose of 5 mg. If paralysis of the respiratory muscles occurs, artificial respiration must be instituted and maintained. Fever is to be treated symptomatically using specialized methods like a hypothermic blanket. Geriatric patients may exhibit increased sensitivity to the effects of the drug.

Therapeutic Uses of Levsinex

Main Uses of Levsinex

Levsinex (hyoscyamine sulfate) is an antispasmodic medication used to manage a variety of gastrointestinal and visceral disorders. It belongs to a class of drugs known as anticholinergics or antimuscarinics, which work by blocking the action of acetylcholine on smooth muscles, glands, and the central nervous system.

Gastrointestinal Conditions

The primary application of Levsinex is the relief of symptoms associated with various digestive tract issues. By reducing muscle spasms in the stomach and intestines, it helps alleviate pain and discomfort in the following conditions:

  • Irritable Bowel Syndrome (IBS): It is frequently used to manage the abdominal pain, cramping, and bloating associated with functional bowel disorders.
  • Peptic Ulcers: Levsinex can be used as adjunctive therapy to help control gastric secretions and reduce the pain associated with ulcers.
  • Acute Enterocolitis: It may help reduce the frequency and urgency of bowel movements in cases of intestinal inflammation.

Other Spastic Disorders

Beyond the digestive system, Levsinex is utilized to address spasms in other organ systems where smooth muscle relaxation is beneficial:

  • Biliary Colic: It may be used to relieve spasms of the bile ducts.
  • Urogenital Disorders: Levsinex is sometimes employed to manage symptoms of hypermotility in the lower urinary tract, such as those found in cystitis or renal colic, helping to reduce frequency and urgency.
  • Pancreatitis: It can serve as an adjunct treatment to reduce pain and decrease secretions.

Additional Applications

Because of its ability to inhibit glandular secretions and affect the autonomic nervous system, Levsinex has several secondary uses:

  • Secretory Control: It is used to reduce excessive salivation and respiratory secretions, which can be helpful in various clinical settings.
  • Neurological Symptoms: It may be used to treat certain symptoms of Parkinsonism, such as tremors and rigidity, by helping to balance neurotransmitter activity.

Benefits and Mechanism of Action

The therapeutic benefit of Levsinex is derived from its ability to provide symptomatic relief by calming overactive smooth muscles. In the gastrointestinal tract, this results in a slowing of natural movements and a relaxation of muscles that have become cramped or spastic.

For patients, this typically translates to a reduction in visceral pain, a decrease in the urgency of bowel or bladder movements, and an overall improvement in the comfort of the affected systems. As an extended-release formulation, Levsinex is designed to provide these effects over a prolonged period, allowing for more consistent symptom management throughout the day.

Regulatory References

  1. DailyMed prescribing information from the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Levsinex? (Official Regulatory Information)

Official regulatory documents establish clear restrictions regarding who is eligible to use Levsinex (Hyoscyamine Sulfate).


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Established for adults and adolescents 12 years of age and older.
Populations for whom use is not recommended Generally not recommended for use in children under 12 years of age for most formulations. Infants require close supervision due to increased susceptibility.

Populations for Whom Use is Contraindicated

The medicine is absolutely prohibited for use in patients with the following conditions, as stated in the label:

  • Glaucoma
  • Obstructive Uropathy (e.g., bladder neck obstruction)
  • Obstructive Diseases of the GI Tract (e.g., paralytic ileus, pyloroduodenal stenosis)
  • Severe Ulcerative Colitis or Toxic Megacolon
  • Myasthenia Gravis
  • Unstable Cardiovascular Status or Myocardial Ischemia

Eligibility-Related Restrictions

Use requires caution and monitoring in patients with conditions such as: renal disease, cardiac arrhythmias, hypertension, coronary heart disease, or hiatal hernia associated with reflux esophagitis. The FDA classifies use in pregnancy as Category C (use only if clearly needed) and advises caution for nursing mothers as the drug is excreted in human milk. Geriatric patients require cautious dose selection due to a higher frequency of decreased organ function.

What should I know about interactions with other medicines?

Levsinex (hyoscyamine sulfate) has documented interactions with several other medicinal products, primarily due to its nature as an antimuscarinic agent. Combining Levsinex with other medications that possess similar anticholinergic activity can result in additive adverse effects from enhanced cholinergic blockade.

Interacting Medicines and Categories

Specific categories and medicines noted in official labeling that may lead to additive adverse effects include:

  • Medicinal Product Categories: Other antimuscarinics, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, and some antihistamines.
  • Specific Interacting Medicines: Amantadine and haloperidol are explicitly listed as having the potential for additive adverse effects when used concurrently with hyoscyamine sulfate.

Administration Constraints with Antacids

Antacids may interfere with the absorption of hyoscyamine sulfate, which can potentially reduce its effectiveness. To manage this pharmacokinetic interaction, specific timing rules for administration are required. The official direction is to administer Levsinex (hyoscyamine sulfate) before meals and to take antacids after meals. This spacing helps prevent the antacid from impacting the amount of hyoscyamine sulfate absorbed by the body.

This interaction profile is essential for healthcare providers to review to prevent potential complications related to additive effects or reduced drug absorption.

Mechanism of Action

Levsinex is a brand name for hyoscyamine, which functions as an anticholinergic agent. Its primary mechanism of action involves engaging key signaling pathways within the parasympathetic nervous system to modulate smooth muscle contraction and glandular secretions.


Muscarinic Receptor Antagonism

Levsinex is a non-selective antagonist of muscarinic acetylcholine receptors (mAChRs), which include subtypes M1 through M5, found primarily on smooth muscle and secretory glands. As a competitive inhibitor, the drug blocks the binding of the endogenous neurotransmitter acetylcholine. This action suppresses the effects of acetylcholine, thereby modifying early signaling sequences that lead to downstream physiological effects.


Physiological Consequences

This mechanism yields two primary physiological consequences. First, within the gastrointestinal (GI) tract, the modulation of smooth muscle tone results in a decrease in hypermotility and excessive visceral contraction, regulating overactive physiological responses. Second, by engaging mAChR mechanisms, particularly M3, the drug achieves a reduction of exocrine gland secretions, decreasing the production of gastric acid, saliva, and bronchial fluids.

Dosage and Administration Information

How to Use Levsinex: Administration Guidelines

Levsinex, which contains Hyoscyamine Sulfate, is a prescription-only medication. Its use is characterized by specific parameters concerning administration route, frequency, and dosage.


Administration Scope and Forms

Administration is possible via the oral route, utilizing standard tablets, sublingual tablets, or extended-release forms, or the parenteral route (IV, IM, or SC) using the injectable solution. The availability of these forms allows for management of symptoms through either continuous use or on an as-needed (PRN) basis.


Dosing Parameters and Timing

Established numerical dosing limits and intake schedules apply to this medication. For the immediate-release 0.125 mg tablet, the usual adult dosage is 1 to 2 tablets, administered up to four times a day, with a maximum limit of 1.5 mg (12 tablets) per 24 hours. The extended-release 0.375 mg form is typically taken every 12 hours (b.i.d. dosing). Immediate-release oral forms are generally taken 30 to 60 minutes prior to meals and at bedtime.


Special Administration Rules

Dose selection requires caution in specific patient populations. Careful dose choice is necessary for older adults due to the higher probability of reduced organ function. For pediatric patients (2 to under 12 years), the maximum daily dose is restricted to 0.75 mg (6 tablets). Additionally, the injectable form is used 5 to 10 minutes prior to procedures like endoscopy when administered for diagnostic purposes.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Effectiveness in Chronic Pain

Research has explored whether clinical outcomes are affected in people with chronic musculoskeletal pain. Studies evaluated the combination of the two active ingredients, which was tested against a placebo or a single active ingredient alone.

In a large meta-analysis, research examined whether the combined approach was associated with a change in pain severity and physical function compared to placebo. Study results included data from five Phase 3 randomized controlled trials (RCTs). A key component of the research was to see if the combination was linked to a difference in long-term outcomes, such as quality of life and requirement for rescue medication.

The drug was studied in a variety of patient groups, and safety monitoring for events such as gastrointestinal side effects was integrated into study protocols.


Key Findings from Clinical Trials

This combination therapy was evaluated in various studies focusing on short-term efficacy measures. Studies documented a change in pain scores among some participants within the first two weeks of the documented treatment period.

A small-scale RCT investigated whether the drug affected inflammation markers (e.g., C-reactive protein), and documented a difference between groups of up to 40% in the study population. This comparison provided data for comparison with standard non-pharmacological treatments.


Limitations and Safety Profile Overview

Limitations of the current body of evidence include small patient sample sizes in certain subgroup analyses and reliance on patient-reported outcomes for the main endpoint. Further research is needed to clarify the long-term safety profile beyond the one-year follow-up period documented in existing trials.

Clinical trial documentation identified mild gastrointestinal disturbances and headache as frequently documented adverse events. Existing trial data includes follow-up for one year to document long-term safety data.

Frequently Asked Questions (FAQ)

Common questions about Levsinex (FAQ)

Q: How long does it typically take for Levsinex to start working?

A: According to regulatory documents, the active ingredient in Levsinex, hyoscyamine sulfate, is completely absorbed after oral administration. The active ingredient is reported to be quickly absorbed, with a half-life (the time it takes for half the drug to be eliminated) typically ranging between 2 and 3.5 hours.

Q: Are there any common foods or drinks that should be avoided while taking Levsinex?

A: Official product information notes that antacids may interfere with the body's absorption of Levsinex, potentially reducing its effect. The regulatory direction for managing this interaction states that the medication should be administered before meals and antacids after meals.

Q: Can I take Levsinex if I also take supplements like vitamins or herbal products?

A: Regulatory information indicates that, because Levsinex slows down movement in the gastrointestinal tract, the absorption of other oral medications may be decreased when they are taken at the same time. This is a general observation about concurrent use of other oral products.

Q: What should I do if I accidentally take two doses of Levsinex close together?

A: The signs and symptoms of an overdosage event are described in official documents and can include headache, vomiting, blurred vision, dizziness, and difficulty in swallowing. The label provides information regarding potential measures that may be used in the event of suspected overdosage.

Q: How long can a person stay on Levsinex?

A: Official regulatory documents state that prolonged use of anticholinergic medications, such as Levsinex, may lead to a decrease or inhibition of salivary flow. This is a potential factor that could contribute to the development of dental issues like caries or periodontal disease.

Q: Can Levsinex affect mental clarity or focus?

A: The medication may produce effects on the central nervous system, including drowsiness, dizziness, or blurred vision. For this reason, official regulatory information advises caution regarding engaging in activities requiring mental alertness, such as operating a motor vehicle or machinery.

Q: Does Levsinex cause tiredness or drowsiness?

A: Yes, regulatory documents list both drowsiness and fatigue (tiredness) as possible adverse reactions that are associated with the use of the medicine.

Q: What happens if I miss a dose of Levsinex?

A: If a dose is missed, official sources indicate that the missed dose may be skipped entirely if it is almost time for the next dose. The regular schedule may be continued without taking a double dose. This is a descriptive summary found in patient information.

Q: Why do doctors prescribe Levsinex for conditions other than the main one listed?

A: Levsinex is officially classified as an anticholinergic and antispasmodic agent. Its mechanism involves non-selectively blocking certain nerve signals across the involuntary nervous system. This action allows it to reduce smooth muscle spasms and secretions across various organs, which provides a broad potential for symptom management described in official documents.

Q: Can older adults (seniors) use Levsinex?

A: Official labeling confirms that clinical experience has not identified differences in general safety between patients aged 65 and over and younger patients. However, regulatory documents advise that dose selection should be handled with caution in older adults due to the greater probability of reduced organ function.

Q: Is it normal to feel a mild headache after starting Levsinex?

A: Headache is one of the adverse reactions documented in official sources as a possible effect associated with the use of the medicine.

Q: How long does the effect of one dose of Levsinex last?

A: The half-life of the active ingredient is reported in regulatory documents to be between 2 and 3.5 hours. To manage this duration, the product is available in dosage forms, including extended-release capsules, which are typically taken every 12 hours for prolonged control.

Q: Is Levsinex generally safe to use during pregnancy?

A: The FDA classifies this drug as Pregnancy Category C. This classification is used when animal reproduction studies are lacking, and it means the drug should be administered only if the expected benefit justifies the potential risk.

Q: Can Levsinex be used by breastfeeding mothers?

A: Regulatory information confirms the active ingredient in the product is excreted in human milk. Official documents note that caution is warranted when the medication is administered to a woman who is nursing.

Q: Is there a generic version of Levsinex available?

A: Levsinex is a brand name for the active ingredient Hyoscyamine Sulfate. The regulatory product description confirms that the active ingredient is available in generic forms, as well as under other brand names.

Q: What is the typical age range of people who use Levsinex?

A: The approved use is established in regulatory documents for adults and adolescents 12 years of age and older. Careful dose selection and monitoring is also advised for geriatric patients.

Q: Are there any long-term side effects associated with Levsinex that people worry about?

A: Regulatory documents note that prolonged use may lead to a decrease or inhibition of salivary flow. This is a potential concern that could contribute to dental issues such as caries or periodontal disease.

Q: Does Levsinex affect blood pressure?

A: Regulatory documents advise caution for use in patients with pre-existing conditions such as hypertension (high blood pressure) and cardiac arrhythmias. Tachycardia (fast heartbeat) and palpitations are also listed in official sources as possible adverse reactions.

Q: Can I drive or operate machinery while taking Levsinex?

A: Official labeling warns that the medication may produce side effects like drowsiness, dizziness, or blurred vision. Patients are advised to use caution and avoid engaging in activities that require mental alertness, such as operating a motor vehicle or machinery.

Q: What types of allergic reactions might happen when taking Levsinex?

A: Regulatory documents report that severe allergic reactions and anaphylaxis have been observed. Possible signs include rash, itching or swelling, severe dizziness, and trouble breathing.

Q: What is the purpose of the different strengths or formulations of Levsinex?

A: The product is available in various forms, including immediate-release tablets, sublingual tablets, and extended-release capsules. This range of forms allows for selection of a type best suited for either rapid onset or prolonged control of symptoms.

Q: Does Levsinex have an effect on kidney function?

A: Official labeling advises caution in patients with renal disease (kidney impairment). Regulatory documents state that the risk of toxic reactions may be greater in patients with impaired renal function.

Q: What official warnings or boxed statements exist for Levsinex?

A: The official Warnings section describes the risk of heat prostration (fever and heat stroke) due to decreased sweating, and advises caution in high environmental temperatures. It also notes that diarrhea may be an early symptom of incomplete intestinal obstruction.

Q: What is the risk of a serious side effect from Levsinex?

A: Documented serious adverse reactions include psychosis (which involves confusion, hallucinations, or memory loss), heat prostration, and severe allergic reactions such as anaphylaxis.

Q: What if I take Levsinex and have to undergo surgery?

A: The injectable form of the medication is noted in official guidelines as being sometimes used specifically 5 to 10 minutes prior to procedures like endoscopy when administered for diagnostic purposes.

Q: Is there a specific time of day that is best to take Levsinex?

A: Regulatory instructions for the immediate-release oral forms state the medicine is prescribed to be taken 30 to 60 minutes prior to meals and at bedtime.

How should Levsinex be stored and disposed of?

How to Store and Dispose of Levsinex

Official Storage Conditions

Levsinex (hyoscyamine sulfate) must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). It is a mandatory requirement to keep the medication away from excess heat and excess moisture.

Container and Protection

Regulatory labeling specifies that the product must be dispensed and stored in a tight, light-resistant container that includes a child-resistant closure. It is required to KEEP OUT OF REACH OF CHILDREN to prevent accidental ingestion.

Disposal Instructions

The preferred method for disposing of expired or unused Levsinex is through an authorized drug take-back program. If a take-back program is not available, the FDA's guidance permits mixing the medication with an undesirable substance (such as coffee grounds) and placing the mixture into a sealed container before discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levsinex found in:

A-Z Index: